- Home
- STRW vs LCTX Comparison
STRW vs LCTX Comparison
Compare STRW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- LCTX
- Stock Information
- Founded
- STRW 2015
- LCTX 1990
- Country
- STRW United States
- LCTX United States
- Employees
- STRW N/A
- LCTX N/A
- Industry
- STRW Real Estate Investment Trusts
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRW Real Estate
- LCTX Health Care
- Exchange
- STRW Nasdaq
- LCTX Nasdaq
- Market Cap
- STRW 119.6M
- LCTX 127.7M
- IPO Year
- STRW N/A
- LCTX N/A
- Fundamental
- Price
- STRW $11.18
- LCTX $0.59
- Analyst Decision
- STRW Strong Buy
- LCTX Strong Buy
- Analyst Count
- STRW 5
- LCTX 5
- Target Price
- STRW $12.38
- LCTX $4.80
- AVG Volume (30 Days)
- STRW 119.9K
- LCTX 2.4M
- Earning Date
- STRW 11-08-2024
- LCTX 03-06-2025
- Dividend Yield
- STRW 4.65%
- LCTX N/A
- EPS Growth
- STRW 23.40
- LCTX N/A
- EPS
- STRW 0.51
- LCTX N/A
- Revenue
- STRW $112,050,000.00
- LCTX $8,719,000.00
- Revenue This Year
- STRW N/A
- LCTX N/A
- Revenue Next Year
- STRW $9.02
- LCTX $41.15
- P/E Ratio
- STRW $21.97
- LCTX N/A
- Revenue Growth
- STRW 14.46
- LCTX N/A
- 52 Week Low
- STRW $6.56
- LCTX $0.48
- 52 Week High
- STRW $12.90
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- STRW 54.67
- LCTX 51.92
- Support Level
- STRW $10.95
- LCTX $0.54
- Resistance Level
- STRW $11.35
- LCTX $0.60
- Average True Range (ATR)
- STRW 0.43
- LCTX 0.04
- MACD
- STRW 0.12
- LCTX 0.01
- Stochastic Oscillator
- STRW 70.47
- LCTX 82.62
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.